DNMT3A and acute myeloid leukemia: To analyze the transferability of the prognostic relevance of our initial grouping of gene mutation profiles of DNMT3A-mutated TCGA AML patients into a short- and long-lived subgroup (Fig. 1A, Supplementary Table 1), we considered gene mutation data of 208 DNMT3A-mutant AML patients from the German-Austrian AML Study Group that were initially treated in a similar manner followed by a bone marrow transplantation.